Sourcing Remdesivir O-Desphosphate Acetonide Impurity: Chiral Deprotection & Catalyst Poisoning Risks
Chiral Deprotection Dynamics: Managing Enantiomeric Excess Drift in Remdesivir O-Desphosphate Acetonide Impurity Synthesis
In the synthesis of Remdesivir O-Desphosphate Acetonide Impurity, also referred to as Remdesivir Acetonide Nitrile Impurity, the chiral integrity of the tetrahydrofurodioxole scaffold is paramount. The acetonide protecting group, introduced to shield the 2',3'-diol of GS-441524, is typically removed under mildly acidic conditions. However, process chemists must vigilantly monitor enantiomeric excess (ee) during deprotection, as prolonged exposure to even trace protic acids can catalyze epimerization at the C-1' nitrile-bearing carbon. This drift is often insidious, manifesting as a gradual increase in the undesired (S)-epimer, which co-elutes closely with the target impurity in standard reversed-phase HPLC methods. Field experience shows that using a chiral stationary phase like Chiralpak IA with a hexane/ethanol/diethylamine mobile phase can resolve these epimers, but the real challenge lies in kinetic control. Quenching the deprotection with a chilled phosphate buffer (pH 7.0) immediately after TLC confirmation minimizes epimerization. For those sourcing this GS-5734 Impurity, it is critical to request a chiral purity certificate, as even 0.5% of the wrong enantiomer can skew biological assay results in antiviral research.
When scaling up, the choice of acid becomes a process-defining decision. While p-toluenesulfonic acid (PTSA) in methanol/water is common, its residual presence can catalyze slow degradation during storage. An alternative approach using Dowex 50WX8 resin in H+ form offers a heterogeneous deprotection, simplifying workup and reducing the risk of chiral erosion. Our team has observed that the Remdesivir Acetonide Nitrile Impurity exhibits a peculiar solubility behavior: at temperatures below 5°C, it tends to form a gelatinous mass in pure water, complicating filtration. Adding 10% v/v ethanol to the quench medium prevents this, ensuring smooth isolation. This non-standard parameter is rarely documented but is crucial for consistent recovery.
For a deeper dive into analytical challenges, refer to our guide on UPLC peak tailing and buffer compatibility for this impurity, which addresses mobile phase optimization.
Trace Water Tolerance in Anhydrous THF/DCM Mixtures: Impact on Acetonide Formation and Catalyst Poisoning Risks
The formation of the acetonide moiety in Remdesivir O-Desphosphate Acetonide Impurity is a classic ketalization, typically employing 2,2-dimethoxypropane and a catalytic amount of a Lewis or Brønsted acid. However, the reaction's sensitivity to moisture is often underestimated. In anhydrous THF/DCM mixtures, water levels as low as 200 ppm can poison the catalyst—commonly BF3·Et2O or PTSA—by hydrolyzing the activated dimethoxypropane complex. This leads to stalled reactions, incomplete protection, and the generation of a des-acetonide diol impurity that is difficult to purge. For procurement managers, this translates to batch-to-batch variability if the manufacturer does not rigorously control solvent dryness. At NINGBO INNO PHARMCHEM, we implement Karl Fischer titration on every solvent lot before use, rejecting any with water content above 50 ppm for critical steps.
An often-overlooked aspect is the hygroscopic nature of the starting material, GS-441524. Even after vacuum drying, it can retain up to 0.5% water, which is sufficient to deactivate the catalyst in a 100-gram scale reaction. A practical field solution is azeotropic drying with toluene prior to acetonide formation. This step, while adding time, ensures reproducible kinetics and minimizes the formation of the GS-5734 Impurity that arises from incomplete protection. The resulting impurity profile is cleaner, with the target Remdesivir Acetonide Nitrile Impurity typically exceeding 99.0% purity by HPLC at 254 nm.
For Portuguese-speaking teams, our article on UPLC and buffer guidance for this impurity provides additional analytical insights.
Residual Phosphoric Acid Traces: Mitigating Catalyst Poisoning in Multi-Kilogram Production Runs
In the downstream phosphoramidation step of remdesivir synthesis, the O-desphosphate acetonide impurity is a key intermediate. However, residual phosphoric acid from the phosphorylation reaction can carry over if the workup is not meticulous. This acidic residue acts as a potent catalyst poison in subsequent steps, particularly if the impurity is to be used as a reference standard in catalytic hydrogenation studies. Even 0.1% w/w phosphoric acid can deactivate palladium catalysts, leading to incomplete reductions and off-spec product. Our process engineering team has developed a rigorous washing protocol: after phase separation, the organic layer is washed with 5% aqueous sodium bicarbonate until the aqueous phase pH remains above 7.5, followed by a brine wash and drying over anhydrous sodium sulfate. This reduces residual acidity to below 0.01% as measured by titration.
For bulk purchasers, it is essential to specify a limit for non-volatile acidity in the certificate of analysis (COA). We routinely include this parameter, reporting it as µeq/g. A typical batch of our Remdesivir O-Desphosphate Acetonide Impurity shows less than 5 µeq/g, ensuring compatibility with sensitive catalytic processes. This level of detail is what distinguishes a research chemical supplier from a true pharmaceutical grade partner.
Temperature-Controlled Crystallization Protocols for Maintaining ≥99.0% ee in Bulk Remdesivir Impurity
Achieving high enantiomeric purity in the final isolated solid requires precise control over crystallization. The Remdesivir O-Desphosphate Acetonide Impurity exhibits a strong tendency to form conglomerate crystals, where each crystal is enantiomerically pure, but the bulk solid can be racemic if crystallization is not seeded. Our protocol involves dissolving the crude product in hot isopropanol (60°C), then cooling to 45°C and seeding with 1% w/w of the desired enantiomer. The mixture is then cooled to 0°C over 6 hours with linear ramping. This controlled cooling profile is critical; rapid cooling leads to oiling out and entrapment of the undesired enantiomer. The resulting crystalline solid consistently shows ≥99.5% ee by chiral HPLC.
A non-standard parameter we monitor is the crystal habit. Under slow cooling, the impurity forms long, needle-like crystals that can occlude mother liquor, trapping impurities. Adding 2% v/v of ethyl acetate to the crystallization solvent modifies the habit to compact prisms, improving filtration and purity. This hands-on knowledge ensures that every kilogram shipped meets the stringent requirements of analytical standard applications.
| Parameter | Specification | Typical Value |
|---|---|---|
| Purity (HPLC, 254 nm) | ≥98.0% | 99.2% |
| Enantiomeric Excess (ee) | ≥99.0% | 99.7% |
| Water Content (KF) | ≤0.5% | 0.1% |
| Residual Solvents (GC) | ICH Q3C compliant | Ethanol <100 ppm, Isopropanol <500 ppm |
| Non-volatile Acidity | ≤10 µeq/g | 3 µeq/g |
These specifications are representative; please refer to the batch-specific COA for exact values.
Bulk Packaging and COA Parameters: Ensuring Supply Chain Integrity for Remdesivir O-Desphosphate Acetonide Impurity
For industrial procurement, packaging is not merely a logistical afterthought—it is a critical quality parameter. Our Remdesivir O-Desphosphate Acetonide Impurity is typically supplied in 210L HDPE drums with tamper-evident seals for multi-kilogram orders, or in 1kg and 5kg aluminum foil bags under nitrogen for smaller quantities. The material is hygroscopic and light-sensitive; prolonged exposure to ambient humidity can lead to hydrolysis of the acetonide group, generating the diol impurity. Therefore, each container is purged with dry nitrogen and includes a desiccant pouch. We also offer IBC totes for ton-scale requirements, with moisture-indicating silica gel vents to maintain integrity during transit.
Every shipment is accompanied by a comprehensive COA that includes not only the standard identity, purity, and ee tests but also residual solvent analysis per ICH Q3C, heavy metals by ICP-MS, and a specific test for the des-acetonide impurity. For clients requiring additional assurance, we can provide a statement of GMP compliance for the manufacturing process, though the product itself is labeled for R&D use only. As a global manufacturer with deep expertise in antiviral intermediate synthesis, we understand that supply chain reliability is as important as chemical purity. Our dual-site manufacturing strategy ensures uninterrupted supply, even during peak demand.
For those evaluating custom synthesis options, we can tailor the impurity profile to match specific research needs, such as enriching a particular stereoisomer or providing a certified reference standard. Explore our product page for Remdesivir O-Desphosphate Acetonide Impurity (CAS 1191237-80-5) with high purity to request a quote or sample.
Frequently Asked Questions
What is the typical batch-to-batch variability in enantiomeric excess for this impurity?
Under our controlled crystallization protocol, batch-to-batch ee variability is typically within ±0.3%. We have observed that minor fluctuations in seeding temperature (±2°C) can shift ee by up to 0.5%, so strict adherence to the cooling profile is enforced. Each batch is independently verified by chiral HPLC, and the COA reflects the exact value.
What are the acceptable limits for residual solvents according to ICH Q3C?
For this impurity, the primary residual solvents are isopropanol (Class 3, limit 5000 ppm) and ethyl acetate (Class 3, limit 5000 ppm). We also monitor for dichloromethane (Class 2, limit 600 ppm) if used in earlier steps. Our typical batches show isopropanol below 500 ppm and no detectable dichloromethane, well within ICH Q3C guidelines for pharmaceutical impurities.
How do different crystallization solvents affect the polymorphic form distribution?
The impurity crystallizes in a single, stable polymorphic form from isopropanol or ethanol/water mixtures. However, using acetonitrile as a co-solvent can induce a metastable polymorph that exhibits broader XRD peaks and slightly lower melting point. This metastable form has identical chemical purity but may show different dissolution rates. For consistency, we exclusively use isopropanol for final crystallization unless a client specifically requests an alternative solvent system for their research.
Sourcing and Technical Support
Securing a reliable supply of high-purity Remdesivir O-Desphosphate Acetonide Impurity is a strategic decision that impacts the reproducibility of your antiviral research and process development. From managing chiral integrity during deprotection to mitigating catalyst poisoning risks in multi-step syntheses, the technical nuances demand a supplier with deep process knowledge and robust quality systems. At NINGBO INNO PHARMCHEM, we combine field-tested manufacturing protocols with rigorous analytical oversight to deliver a product that consistently meets the most demanding specifications. Whether you need gram quantities for method development or multi-kilogram batches for pilot studies, our team is equipped to support your timelines with transparent communication and technical documentation. Partner with a verified manufacturer. Connect with our procurement specialists to lock in your supply agreements.